1 quality by design - a generic industry perspective edmund m. fry vice president of compliance ivax...
TRANSCRIPT
1
Quality By Design - A Generic Industry Perspective
Edmund M. Fry
Vice President of Compliance
IVAX Corp.
Generic Pharmaceutical Association
2
A shared vision of quality
GPhA supports the FDA CGMP initiative Generic drug manufacturing companies:
Exist to make affordable drug therapies available to all
Companies, staff, volumes and revenues are smaller
It is completely appropriate that regulatory requirements apply to all companies small and large, as long as regulatory guidance provides flexibility in recognition of more limited resources at smaller firms
3
What is Quality by Design?
“You can’t test quality into drug products” has been heard for decades – so what’s new? It’s a culture - incorporates quality principles as well
as strong compliance function Incorporates risk assessment and management Refocuses attention and resources on what’s
important to the customer, i.e. the patients, health professionals, payors and distribution chain
4
Quality by Design
Continuous improvement is a hallmark of quality by design G. Taguchi on Robust Design: design changes
during manufacture can result in the last product produced being different from the first product
In pharmaceutical manufacturing, we don’t want this – patients and physicians must count on each batch of drug working just like the batches that came before
5
Quality by Design
In generic pharmaceutical manufacturing, there are additional constraintsFixed bioequivalence targetsRegulatory requirements to duplicate
formulation of innovator drugLack of access to innovator development
data
6
The Changing Environment
Quality by Design
Adequate resources for quality: number, qualifications, etc.
Self-assessments play key role
Continuous analysis & improvement
Change management based on good science
Focus on what’s important (risk management)
Current Regulatory Situation
Little guidance on adequate resources or qualifications
Self-assessments not trusted Annual product reviews
instead of continuous analysis
Formidable barriers to change, including intimidating enforcement emphasis
Seldom admit that anything is not important; test everything
7
Suggested actions
Give credit for good performance Continue to reduce unnecessary supplements Continue to develop the Pharmaceutical
Inspectorate Reward process innovation Eliminate unnecessary testing requirements Address oversight of overseas API mfrs
8
Give credit for good performance
Proven ability to operate in compliance should result in reduced regulatory burden, e.g. inspections and pre-approval review requirements
Factors considered by FDA in assigning inspections (D. Horowitz, Sept. 10, ’03): Facility (e.g., compliance history) Product being manufactured at the facility Process used (e.g., process understanding)
Generic pharmaceutical manufacturers must be rated on the same basis as larger companies
9
Continue to reduce pre-approval supplements
ExamplesNew manufacturing sitesPost-approval changes for sterile
products
10
Continue to develop the Pharmaceutical Inspectorate
FDA is doing a good job of raising technical competence of Investigators
System-based inspections are a meaningful approach
Further opportunities exist to integrate field activities with review activities; integrated uniform training; delegation of more decisions to field personnel
11
Reward process innovation
PAT holds promise; effort actually led by FDA instead of industry
Similar encouragement should be provided for other advancing technologies (e.g. advanced aseptic processing)
12
Eliminate unnecessary testing and other requirements
Prime example: sterility testingBlend uniformity testing
13
Address oversight of overseas API mfrs
Use data from pharmaceutical companies
Support pooling audit information
14
International Initiatives
Continue to include all affected parties in policy-making initiatives
Due to the nature of the generic pharmaceutical industry, we may not have equivalent numbers of senior-level technical personnel who can dedicate substantial extramural time to working with ICH and other international activities
However, that does not mean we can’t be at the table
15
Conclusion
Quality by Design and the FDA CGMP Initiative make excellent business and scientific sense
The generic pharmaceutical industry welcomes the opportunity to work with FDA